Multiple late complications of therapy with cyclophosphamide, including ovarian destruction.
D000293:Adolescent; D000578:Amidines / Q000008:administration & dosage; D001171:Arthritis, Juvenile / Q000150:complications / Q000188:drug therapy; D001344:Autopsy; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006470:Hemorrhage / Q000150:complications; D006801:Humans; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008168:Lung / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis; D009205:Myocarditis / Q000150:complications; D010049:Ovarian Diseases / Q000139:chemically induced* / Q000473:pathology; D010053:Ovary / Q000473:pathology; D010493:Pericarditis / Q000150:complications; D010496:Pericardium / Q000473:pathology; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D013902:Radiography, Thoracic; D013451:Sulfonic Acids / Q000008:administration & dosage; D014552:Urinary Tract Infections / Q000150:complications
D000578:Amidines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013451:Sulfonic Acids; D003520:Cyclophosphamide; D011241:Prednisone